| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 24,232 | 12,485 | 13,864 | 32,171 |
| Deferred tax expense | 10 | -8,146 | 8 | 23 |
| Foreign currency exchange rate loss | NaN | 0 | NaN | 0 |
| Non-cash interest expense | 279 | 155 | 279 | NaN |
| Depreciation and amortization | 1,483 | 1,367 | 1,268 | 2,313 |
| Loss on disposal of property and equipment | -52 | 0 | 0 | -79 |
| Stock-based compensation expense | 19,721 | 34,799 | 32,173 | 64,895 |
| Bad debt expense | 4,436 | 5,181 | 4,328 | 11,017 |
| Net accretion of discounts on marketable securities | -1,150 | 434 | 459 | -27 |
| Accounts receivable | 47,773 | -27,038 | -15,011 | 47,166 |
| Prepaid expenses and other current assets | -9,601 | -2,912 | 6,913 | 7,946 |
| Accounts payable | 33,635 | 1,092 | -17,547 | 45,207 |
| Accrued expenses and other current liabilities | 1,530 | -12,900 | 7,465 | 5,852 |
| Non-cash interest income | NaN | NaN | NaN | 0 |
| Other noncurrent assets and liabilities | 2,407 | 9,346 | -1,194 | 1,154 |
| Net cash provided by operating activities | 45,949 | 54,203 | 50,671 | 105,318 |
| Purchase of property and equipment, net | 6,347 | 5,614 | 4,684 | 8,112 |
| Purchase of marketable securities | 0 | 43,451 | 111,425 | 200,088 |
| Sale of marketable securities | 102,941 | 57,321 | 73,365 | 93,015 |
| Acquisition of business, net of cash acquired | 0 | 0 | 0 | 9,340 |
| Net cash provided by (used in) investing activities | 96,594 | 8,256 | -42,744 | -124,525 |
| Repurchase of common stock | 118,607 | 81,657 | 0 | 0 |
| Proceeds from exercise of stock options | 30 | 63 | 5 | 18 |
| Issuance costs on credit facility | NaN | 0 | 3,087 | NaN |
| Payment of employee taxes related to equity awards | 4,844 | 7,028 | 2,625 | 6,195 |
| Proceeds from contributions to employee stock purchase plan | 307 | 363 | 221 | 560 |
| Net cash used in financing activities | -123,114 | -88,259 | -5,486 | -5,617 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | -51 | 13 | -3 | 52 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 19,378 | -25,787 | 2,438 | -24,772 |
| Cash, cash equivalents, and restricted cash, beginning of period | 114,193 | 139,980 | 162,314 | NaN |
| Cash, cash equivalents, and restricted cash, end of period | 133,571 | 114,193 | 139,980 | NaN |
Progyny, Inc. (PGNY)
Progyny, Inc. (PGNY)